Povidone-iodine Antisepsis for Strabismus Surgery

NCT00461656 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2013-03-05

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy of 5 % vs. 1.25 % povidone-iodine (PI) as preoperative antiseptic prior to strabismus surgery in children as a prophylaxis of endophthalmitis. Given the low rate of endophthalmitis the conjunctival bacterial flora rate is used as surrogate marker to determine the effectiveness of topical PI in reducing or eliminating bacteria from the ocular surface at the time of the surgery. Secondary objective is a reduction of the incidence of postoperative endophthalmitis after strabismus surgery in young children.

Conditions

  • Strabismus
  • Surgery
  • Endophthalmitis

Interventions

DRUG

Preoperative conjunctival irrigation with 5% or 1.25% PI

Before initiation of surgery, children will have their conjunctival fornices irrigated with 5 ml PI 5% or with 5 ml PI 1.25%

Sponsors & Collaborators

  • Ludwig-Maximilians - University of Munich

    collaborator OTHER
  • University Medicine Greifswald

    collaborator OTHER
  • Free University Medical Center

    collaborator OTHER
  • Leiden University Medical Center

    collaborator OTHER
  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    collaborator OTHER
  • Rotterdam Eye Hospital

    collaborator UNKNOWN
  • Laurentius Hospital Roermond

    collaborator UNKNOWN
  • Martin-Luther-Universität Halle-Wittenberg

    collaborator OTHER
  • Erasmus Medical Center

    lead OTHER

Principal Investigators

  • Huibert J Simonsz, MD PhD · Erasmus Medical Center

  • Herminia Miño de Kaspar, PhD · Universitäts-Augenklinik Ludwig-Maximilian University Munich Germany

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Max Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Germany
  • Netherlands

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00461656 on ClinicalTrials.gov